Diagnosis and management of epithelial ovarian cancer

被引:153
作者
Bhoola, Snehal [1 ]
Hoskins, William J. [1 ]
机构
[1] Mem Hlth Univ Med Ctr, Curtis & Elizabeth Anderson Canc Inst, Savannah, GA 31403 USA
关键词
D O I
10.1097/01.AOG.0000220516.34053.48
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States. Although there has been a statistically significant improvement in 5-year survival, in 2005 more than 16,000 women were expected to die of this disease. To date, there is no reliable method to screen for ovarian cancer; therefore, the majority of cases are diagnosed with advanced disease. For early ovarian cancer, appropriate surgical staging and adjuvant chemotherapy for selected cases will result in survival rates of 90-95%. For advanced ovarian cancer, survival depends primarily on the success of the initial surgical procedure. Patients with complete cytoreduction to microscopic disease are often cured with adjuvant chemotherapy. There is growing evidence that these patients with microscopic residual disease are excellent candidates for intraperitoneal chemotherapy, and this mode of chemotherapy delivery may be their best opportunity for cure. Patients with optimal cytoreduction also may benefit from intraperitoneal chemotherapy, but cure is less likely. For patients with suboptimal cytoreduction, intravenous chemotherapy with a combination of carboplatin and paclitaxel is the current standard therapy. Most of these patients will experience recurrence of the cancer, with small chance of cure. Salvage chemotherapy is important in ovarian cancer because many patients respond to several salvage regimens. Because of the high response rate of ovarian cancer, even after relapse, it is probably better to consider 10-year survival as the ideal end point. Finally, new biologic agents, in combination with traditional surgery and chemotherapy, may result in further improvement in survival for patients with ovarian cancer.
引用
收藏
页码:1399 / 1410
页数:12
相关论文
共 86 条
[71]  
TRIMBOS JB, 1991, CANCER, V67, P597, DOI 10.1002/1097-0142(19910201)67:3<597::AID-CNCR2820670313>3.0.CO
[72]  
2-A
[73]   THE EFFECT OF DEBULKING SURGERY AFTER INDUCTION CHEMOTHERAPY ON THE PROGNOSIS IN ADVANCED EPITHELIAL OVARIAN-CANCER [J].
VANDERBURG, MEL ;
VANLENT, M ;
BUYSE, M ;
KOBIERSKA, A ;
COLOMBO, N ;
FAVALLI, G ;
LACAVE, AJ ;
NARDI, M ;
RENARD, J ;
PECORELLI, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :629-634
[74]  
VANNAGELL JR, 1990, CANCER, V65, P573, DOI 10.1002/1097-0142(19900201)65:3<573::AID-CNCR2820650331>3.0.CO
[75]  
2-4
[76]   Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients [J].
Vergote, I ;
De Wever, I ;
Tjalma, W ;
Van Gramberen, M ;
Decloedt, J ;
van Dam, P .
GYNECOLOGIC ONCOLOGY, 1998, 71 (03) :431-436
[77]   Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma [J].
Vergote, I ;
De Brabanter, J ;
Fyles, A ;
Bertelsen, K ;
Einhorn, N ;
Sevelda, P ;
Gore, ME ;
Kærn, J ;
Verrelst, H ;
Sjövall, K ;
Timmerman, D ;
Vandewalle, J ;
Van Gramberen, M ;
Tropé, CG .
LANCET, 2001, 357 (9251) :176-182
[78]  
VOGL SE, 1983, CANCER, V51, P2024, DOI 10.1002/1097-0142(19830601)51:11<2024::AID-CNCR2820511111>3.0.CO
[79]  
2-I
[80]   FACTORS INFLUENCING SURVIVAL IN STAGE 1 OVARIAN CANCER [J].
WEBB, MJ ;
DECKER, DG ;
MUSSEY, E ;
WILLIAMS, TJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1973, 116 (02) :222-228